MX2011012131A - Perhexilina para usarla en el tratamiento de miocardiopatía hipertrófica (hcm). - Google Patents

Perhexilina para usarla en el tratamiento de miocardiopatía hipertrófica (hcm).

Info

Publication number
MX2011012131A
MX2011012131A MX2011012131A MX2011012131A MX2011012131A MX 2011012131 A MX2011012131 A MX 2011012131A MX 2011012131 A MX2011012131 A MX 2011012131A MX 2011012131 A MX2011012131 A MX 2011012131A MX 2011012131 A MX2011012131 A MX 2011012131A
Authority
MX
Mexico
Prior art keywords
perhexiline
hcm
treatment
hypertrophic cardiomyopathy
treating
Prior art date
Application number
MX2011012131A
Other languages
English (en)
Other versions
MX338099B (es
Inventor
Michael Paul Frenneaux
Houman Ashrafian
Original Assignee
Heart Metabolics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40833905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011012131(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Heart Metabolics Ltd filed Critical Heart Metabolics Ltd
Publication of MX2011012131A publication Critical patent/MX2011012131A/es
Publication of MX338099B publication Critical patent/MX338099B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La invención se refiere a perhexilina, o una sal farmacéuticamente aceptable de la misma, para su uso en el tratamiento de la cardiomiopatia hipertrófica, así como a un método para tratar la HCM, que comprende administrar a un animal que necesite de la misma una cantidad efectiva de perhexilina, o una sal farmacéuticamente aceptable de la misma, para tratar dicha HCM; la invención también se refiere a un programa de tratamiento para tratar la HCM, que comprende el uso simultáneo o la coadministración de perhexilina con uno o más de otros compuestos que sean ventajosos en el tratamiento de la HCM o los síntomas de la misma.
MX2011012131A 2009-05-13 2010-05-11 Perhexilina para usarla en el tratamiento de miocardiopatía hipertrófica (hcm). MX338099B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0908193.6A GB0908193D0 (en) 2009-05-13 2009-05-13 Treatment of disease state
PCT/GB2010/050770 WO2010131033A1 (en) 2009-05-13 2010-05-11 Perhexiline for use in the treatment of hypertrophic cardiomyopathy (hcm)

Publications (2)

Publication Number Publication Date
MX2011012131A true MX2011012131A (es) 2012-03-07
MX338099B MX338099B (es) 2016-04-01

Family

ID=40833905

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012131A MX338099B (es) 2009-05-13 2010-05-11 Perhexilina para usarla en el tratamiento de miocardiopatía hipertrófica (hcm).

Country Status (14)

Country Link
US (2) US8697728B2 (es)
EP (1) EP2429525A1 (es)
JP (2) JP2012526792A (es)
CN (2) CN107296810A (es)
AU (1) AU2010247120B2 (es)
BR (1) BRPI1007779A2 (es)
CA (1) CA2799087A1 (es)
CL (1) CL2011002862A1 (es)
GB (1) GB0908193D0 (es)
IL (1) IL216288A0 (es)
MX (1) MX338099B (es)
NZ (1) NZ597031A (es)
WO (1) WO2010131033A1 (es)
ZA (1) ZA201109184B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405381D0 (en) 2004-03-10 2004-04-21 Univ Wales Medicine A method and means for treating heart failure
GB0908193D0 (en) 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
EP2432470A1 (en) 2009-05-20 2012-03-28 Heart Metabolics Limited Treatment of heart failure with normal ejection fraction
EP2892529A4 (en) * 2012-09-05 2016-01-20 Adelaide Res &Innovation Pty Ltd USES OF (-) - PERHEXILINE
US9340443B2 (en) 2012-12-13 2016-05-17 Corning Incorporated Bulk annealing of glass sheets
TN2015000553A1 (en) * 2013-06-21 2017-04-06 Myokardia Inc Pyrimidinedione compounds against cardiac conditions
KR20160145062A (ko) 2014-04-09 2016-12-19 코닝 인코포레이티드 디바이스 변경된 기판 물품 및 제조 방법
JP2018524201A (ja) 2015-05-19 2018-08-30 コーニング インコーポレイテッド シートをキャリアと結合するための物品および方法
JP7106276B2 (ja) 2015-06-26 2022-07-26 コーニング インコーポレイテッド シート及び担体を有する物品及び方法
WO2017153850A1 (en) * 2016-03-07 2017-09-14 Heart Metabolics Limited Perhexiline dosing regimens for use in the treatment of hypertrophic cardiomyopathy
TW201825623A (zh) 2016-08-30 2018-07-16 美商康寧公司 用於片材接合的矽氧烷電漿聚合物
TWI810161B (zh) 2016-08-31 2023-08-01 美商康寧公司 具以可控制式黏結的薄片之製品及製作其之方法
CN111615567B (zh) 2017-12-15 2023-04-14 康宁股份有限公司 用于处理基板的方法和用于制备包括粘合片材的制品的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN380695A0 (en) 1995-06-23 1995-07-20 Queen Elizabeth Hospital, The Methods related to the treatment of and isolation of compounds for treatment of ischaemic conditions
US20030162824A1 (en) 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
CL2004000366A1 (es) 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
GB0405381D0 (en) * 2004-03-10 2004-04-21 Univ Wales Medicine A method and means for treating heart failure
AU2005230811A1 (en) 2004-04-06 2005-10-20 Angiogenetics Sweden Ab Angiogenesis-affecting compounds and methods of use thereof
GB0723100D0 (en) 2007-11-23 2008-01-02 Heart Metabolics Ltd Treatment of HFnEF
GB0908193D0 (en) 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
EP2432470A1 (en) 2009-05-20 2012-03-28 Heart Metabolics Limited Treatment of heart failure with normal ejection fraction

Also Published As

Publication number Publication date
BRPI1007779A2 (pt) 2016-02-23
CA2799087A1 (en) 2010-11-18
AU2010247120A1 (en) 2012-01-19
ZA201109184B (en) 2012-08-29
JP2012526792A (ja) 2012-11-01
EP2429525A1 (en) 2012-03-21
CN107296810A (zh) 2017-10-27
CL2011002862A1 (es) 2012-07-20
WO2010131033A1 (en) 2010-11-18
US8697728B2 (en) 2014-04-15
IL216288A0 (en) 2012-01-31
AU2010247120B2 (en) 2016-06-02
MX338099B (es) 2016-04-01
JP2015232019A (ja) 2015-12-24
CN102481297A (zh) 2012-05-30
NZ597031A (en) 2014-04-30
US20120122925A1 (en) 2012-05-17
GB0908193D0 (en) 2009-06-24
US20140194466A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
MX338099B (es) Perhexilina para usarla en el tratamiento de miocardiopatía hipertrófica (hcm).
EA201101475A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
AU2011328009A8 (en) Compounds and methods for treating pain
CO6630082A2 (es) Tratamiento de lupus nefritis usando laquinimod
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
EA201290919A1 (ru) Индазольные соединения и их применение
MX2011012310A (es) Tratamiento de insuficiencia cardiaca con fracción de eyeccion normal (icfen).
EA200870425A1 (ru) Применение агонистов рецептора grp119 для повышения костной массы и для лечения остеопороза и связанной с ними комбинированной терапии
EA200970933A1 (ru) Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста
CO6630086A2 (es) Tratamiento de artritis por lupus usando laquinimod
WO2009140416A3 (en) Treatment for epilepsy
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
GT200600160A (es) Tratamiento del dolor
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
MX354535B (es) TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß.
MX2014003180A (es) Metodos para tratar vhc.
EA201170425A1 (ru) Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения
MX2009005649A (es) Tratamiento para mieloma multiple.
MY150600A (en) Use of opioid antagonists for treating urinary retention
MX343931B (es) Tratamiento de la esclerosis lateral amiotrofica con el uso de celulas derivadas del cordon umbilical.
MX348898B (es) Métodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales.
MX2013002212A (es) Tratamiento de hipertension y/o prevencion o tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante.
EA201200428A1 (ru) Композиция и способ для лечения ожирения

Legal Events

Date Code Title Description
FG Grant or registration